Vertical Transmission of SARS-CoV-2: What We Know So Far

When SARS-CoV-2 emerged in 2020, clinicians faced an urgent question: could a pregnant person pass the virus to a fetus before birth? The concern was especially important because pregnancy changes respiratory, cardiovascular, and immune physiology, while newborns have immature immune defenses. Early reports were limited by small samples, inconsistent testing, and the practical difficulty of collecting uncontaminated specimens during an outbreak.

Evidence accumulated rapidly through case series, cohort studies, placental investigations, and systematic reviews. The overall picture is now clearer: transmission from mother to fetus can occur, but it is uncommon. Most infants born to people with COVID-19 do not have laboratory evidence of infection at birth, and a positive test in a newborn does not automatically prove infection before delivery.

The subject remains relevant to perinatal and neonatal medicine because timing matters. Infection may arise in the womb, during labor, or after birth through close contact. These routes have different implications for diagnosis, counseling, infection prevention, and neonatal care.

Defining Transmission Before And Around Birth

Vertical transmission generally refers to the passage of an infectious agent from parent to fetus or newborn during pregnancy or delivery. For SARS-CoV-2, researchers often separate congenital or transplacental infection from intrapartum exposure. Postnatal acquisition, including exposure from caregivers or healthcare environments, is considered horizontal transmission rather than vertical transmission.

A positive reverse-transcription polymerase chain reaction result from a nasopharyngeal swab soon after birth can indicate infection, but it does not identify the exact route. Contamination from maternal respiratory secretions, handling, or the delivery environment may produce a positive result. Stronger evidence comes from concordant findings in carefully collected samples, such as amniotic fluid obtained before membrane rupture, placental tissue, umbilical cord blood, neonatal blood, or a neonatal respiratory specimen collected promptly after delivery.

The World Health Organization and neonatal research groups have developed classifications that distinguish confirmed, probable, and possible congenital infection. These frameworks emphasize sample timing, specimen quality, viral detection, and clinical findings. Serology can support the diagnosis, particularly when immunoglobulin M is detected, although interpretation is complicated by assay performance and the possibility of false-positive results.

How SARS-CoV-2 Might Cross The Placenta

The placenta is an active biological barrier rather than a simple filter. Its trophoblast cells, vascular structures, immune components, and antiviral responses can limit pathogens from reaching the fetal circulation. SARS-CoV-2 uses the ACE2 receptor and associated cellular proteins to enter cells, but the levels and distribution of these factors in placental tissues vary with gestational age and disease conditions.

Placental infection has been documented, yet it is not synonymous with fetal infection. In some cases, viral material is found in placental tissue without evidence that the newborn became infected. In other cases, placental inflammation, vascular injury, or viral replication may disrupt the barrier and permit transmission. The risk may be influenced by high maternal viral load, infection close to delivery, severe maternal disease, and placental pathology.

Several mechanisms have been proposed. The virus may cross through infected trophoblasts, damaged placental vessels, or inflammatory pathways that weaken the maternal-fetal interface. Infection can also affect placental blood flow without producing direct fetal infection. Such changes may contribute to fetal growth restriction, preterm birth, or stillbirth, although separating the effects of SARS-CoV-2 from maternal fever, hypoxia, coexisting disease, and obstetric complications is difficult.

What Clinical Studies Have Shown

Across large observational studies, confirmed congenital SARS-CoV-2 infection has remained rare. Reported rates vary because studies use different definitions and testing schedules. Early publications often included suspected cases based on a single neonatal swab, while later studies applied stricter criteria and reported lower estimates. This variation explains why individual percentages should be interpreted cautiously.

The timing of maternal infection appears important. Infection in the third trimester is the most frequently studied because it is easier to connect to delivery and to collect neonatal samples. Transmission after infection earlier in pregnancy may be harder to detect, particularly if the pregnancy continues normally and no samples are available from the relevant period. Miscarriage, stillbirth, and fetal loss can also limit the availability of diagnostic specimens.

Most exposed newborns are asymptomatic or have mild disease. However, a small number of infants with confirmed or strongly suspected congenital infection have presented with respiratory distress, temperature instability, feeding difficulty, neurological signs, thrombocytopenia, or inflammatory abnormalities. These findings are nonspecific, so a complete evaluation must consider prematurity, birth complications, and other neonatal infections.

Distinguishing Congenital, Intrapartum, And Postnatal Infection

The diagnostic window immediately after birth is essential. A newborn swab collected within the first day of life can establish that infection was present around delivery, but repeat testing helps clarify whether the result persists. Testing at different intervals may be recommended according to local neonatal protocols, the infant’s symptoms, and the mother’s infection status.

A newborn who initially tests negative but becomes positive several days later may have acquired SARS-CoV-2 after birth. Close contact, shared rooms, caregivers, visitors, and healthcare workers can all contribute to exposure. This does not imply a failure of care; it reflects how respiratory viruses spread and why layered precautions are used in maternity and neonatal units.

The delivery route has not consistently been shown to eliminate transmission risk. Cesarean birth may be medically necessary for obstetric reasons, but it should not be performed solely to prevent SARS-CoV-2 transmission in an otherwise stable pregnancy. Decisions should account for maternal condition, fetal status, gestational age, viral symptoms, and standard obstetric indications.

Likewise, delayed cord clamping and skin-to-skin contact require individualized assessment rather than automatic prohibition. Current practice in many settings supports these benefits when the parent and infant are clinically stable and appropriate infection-control measures are in place. Policies may change with the level of community transmission, circulating variants, and institutional resources.

Maternal And Newborn Care

Maternal COVID-19 during pregnancy is associated with higher risks of hospitalization, intensive care, preterm birth, and certain obstetric complications, particularly when illness is moderate or severe. These outcomes do not necessarily indicate vertical infection. A fever, respiratory compromise, placental dysfunction, or medically indicated early delivery may affect the newborn even when viral testing is negative.

Care should begin with assessment of maternal respiratory status, oxygenation, hydration, and obstetric wellbeing. Fetal surveillance is guided by gestational age and the severity of maternal illness. Antiviral and supportive treatments should follow current pregnancy-specific guidance, since the risks of untreated COVID-19 must be balanced against medication considerations.

For the newborn, evaluation may include clinical observation, PCR testing, blood studies, and imaging when symptoms warrant it. A well infant with a negative test usually needs routine care with sensible precautions. A symptomatic or positive infant may require respiratory support, blood-gas assessment, sepsis evaluation, or admission to a neonatal unit. Treatment is based on clinical severity, not on a positive PCR result alone.

Breast milk has not been established as a meaningful route of SARS-CoV-2 transmission. Breastfeeding generally provides nutritional and immunological benefits, and milk may contain protective antibodies after maternal infection or vaccination. Hand hygiene, masking when appropriate, cleaning of equipment, and limiting contact from actively ill caregivers can reduce respiratory spread while preserving feeding choices.

Interpreting Placental And Laboratory Evidence

Pathology has added important detail to the discussion. Findings reported in affected pregnancies include chronic histiocytic intervillositis, fibrin deposition, maternal vascular malperfusion, fetal vascular malperfusion, and inflammatory changes. These abnormalities are not unique to SARS-CoV-2, and their presence should be interpreted alongside maternal symptoms, laboratory testing, fetal growth, and neonatal results.

PCR detects viral genetic material, but it does not necessarily demonstrate viable, infectious virus. Immunohistochemistry, in situ hybridization, electron microscopy, and viral culture can provide additional information, although these techniques are not equally available and may produce conflicting findings. Standardized tissue collection and laboratory controls are essential.

Antibody results also require care. Maternal immunoglobulin G crosses the placenta naturally, particularly later in pregnancy, so neonatal IgG may reflect passive transfer rather than fetal infection. Immunoglobulin M is less likely to cross the placenta, but assays can lack specificity. No single test should be treated as definitive when the clinical context and specimen timing point in different directions.

Research teams studying perinatal infection benefit from coordinated definitions and linked maternal-placental-neonatal datasets. The FAOPS 2020 congress archive reflects the wider importance of international collaboration in perinatal and neonatal research, a need made especially visible when the pandemic disrupted scientific meetings and cross-border clinical exchange.

Practical Recommendations For Perinatal Teams

• Use a clear testing pathway that records maternal symptom onset, infection date, membrane status, delivery time, and every neonatal specimen.
• Avoid labeling a newborn case as congenital infection from a single positive swab without reviewing timing, contamination risk, and repeat results.
• Examine the placenta when maternal disease is severe, fetal growth is abnormal, stillbirth occurs, or congenital infection is strongly suspected.
• Preserve breastfeeding, skin-to-skin contact, and family involvement whenever clinically safe, adding hygiene and respiratory precautions as needed.
• Communicate uncertainty honestly, explaining that a negative neonatal test does not erase pregnancy risks and a positive test does not always identify the route of transmission.

What Remains Uncertain

Important questions remain about infection during the first and second trimesters, the effects of emerging variants, and the relationship between placental infection and long-term child development. Many studies have focused on hospitalized or symptomatic patients, so findings may not apply equally to mild or asymptomatic infection. Vaccination and prior immunity also change the clinical landscape and may reduce severe maternal disease while influencing antibody findings in the newborn.

Long-term follow-up is especially valuable. Most infants with perinatal exposure develop normally, but systematic developmental surveillance can identify uncommon effects that short hospital studies cannot detect. Research should include infants who were exposed but never tested positive, since the consequences of maternal inflammation or placental dysfunction may differ from those of direct viral infection.

The strongest current message is balanced: transplacental SARS-CoV-2 transmission is biologically possible and clinically documented, but it is uncommon. Careful specimen collection, consistent definitions, maternal vaccination and treatment, appropriate neonatal monitoring, and protection of essential family contact provide a safer foundation than either minimizing the risk or assuming that every exposed newborn is infected.

Clinicians, researchers, and families can support better evidence by documenting cases precisely, contributing to ethically governed registries, and following updated guidance from reputable obstetric, infectious disease, and neonatal organizations. Continued collaboration will help transform scattered case reports into clearer answers about prevention, diagnosis, and long-term outcomes.